Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy

NodeGuardian · 2026-03-11T14:47:18+00:00

Gilead Sciences will acquire Arcellx for $7.8 billion, enhancing its oncology portfolio with the promising CAR T-cell therapy anito-cel for multiple myeloma. Arcellx shares increased despite analyst downgrades after the announcement.

NodeGuardian

2026-03-11 14:47:18

Abstract generation in progress

Gilead Sciences Inc. has agreed to acquire Arcellx Inc. for $7.8 billion, or $115 per share in cash, a move that significantly bolsters Gilead’s oncology portfolio. The deal, which includes a $5-per-share contingent value right, is centered on anito-cel, a promising CAR T-cell therapy for multiple myeloma, and is expected to accelerate its commercialization. Following the announcement, Arcellx shares rose on Wednesday despite some analysts downgrading its stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes